Cytokinetics CYTK Derivative Liabilities - Fair Value
Derivative Liabilities - Fair Value at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's derivative liabilities - fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's derivative liabilities - fair value?
- Cytokinetics (CYTK) reported derivative liabilities - fair value of $29.6M in Q1 2026.
- How has Cytokinetics's derivative liabilities - fair value changed year-over-year?
- Cytokinetics's derivative liabilities - fair value increased by 153.0% year-over-year, from $11.7M to $29.6M.
- What does derivative liabilities - fair value mean?
- The current market value of financial contracts that the company would have to pay to settle.
- How do you interpret derivative liabilities - fair value?
- An increase indicates that the company's derivative positions are losing value or that market conditions have moved against the company's hedge.
- How does derivative liabilities - fair value compare across companies?
- Depends heavily on the company's hedging strategy and market volatility.